ORIGINAL INVESTIGATION
|
|
- Cynthia Bell
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Age and Duration of Follow-up as Modulators of the Risk for Ischemic Heart Disease Associated With High Plasma C-Reactive Protein Levels in Men Matteo Pirro, MD; Jean Bergeron, MD; Gilles R. Dagenais, MD; Paul-Marie Bernard, MSc; Bernard Cantin, MD, PhD; Jean-Pierre Després, PhD; Benoît Lamarche, PhD Background: Plasma C-reactive protein (CRP) levels recently have been identified as an emerging risk factor for ischemic heart disease (IHD). However, whether plasma CRP levels predict an increased risk for future IHD beyond traditional risk factors has yet to be evaluated in a large prospective, population-based study. Methods: The association between elevated plasma CRP levels and the risk for future IHD was investigated in the prospective, population-based cohort of 2037 IHD-free middle-aged men from the Quebec Cardiovascular Study. During a 5-year follow-up, 105 first IHD events were recorded. Baseline plasma CRP levels were measured using a highly sensitive assay. Results: High plasma CRP concentrations (equal to or above vs below the median level of 1.77 mg/l) were associated with a significant 1.8-fold increase in IHD risk (95% confidence interval [CI], ). This association remained significant after adjustment for lipid risk factors but not when the simultaneous contribution of nonlipid traditional risk factors was taken into account. Multivariate analyses indicated that CRP level predicted short-term risk for IHD (events that occurred 2 years after the baseline evaluation), but not long-term risk ( 2 years). Moreover, high plasma CRP levels predicted an increased risk for IHD, independent of any other confounder, in younger ( 55 years) but not in older ( 55 years) individuals. Conclusion: Plasma CRP levels may provide independent information on IHD risk only in younger middleaged men and in the case of IHD events that may occur relatively soon after the baseline evaluation. Arch Intern Med. 2001;161: From the Lipid Research Center, Laval University Hospital Research Center (Drs Pirro, Bergeron, Cantin, Després, and Lamarche), the Québec Heart Institute, Laval Hospital (Drs Dagenais, Cantin, and Després), and the Department of Social and Preventive Medicine, Laval University (Mr Bernard), Québec City, Québec. ACCUMULATING evidence suggests that inflammation may be etiologically important in the development of atherosclerosis. 1 In this respect, plasma C-reactive protein (CRP), a marker of low to moderate systemic inflammation, has received much attention in recent years. Results from crosssectional and prospective studies 2 have indicated that raised plasma CRP levels were associated with an increased risk for future cardiovascular events among apparently healthy subjects 3,4 as well as in individuals with stable and unstable angina 5 or with previous myocardial infarction. 6 Moreover, results from the Physicians Health Study disclosed that baseline plasma CRP concentration added to the predictive value of traditional lipid risk factors in determining risk for first myocardial infarction. 7 Although these data suggest that adding plasma CRP levels to the list of cardiovascular risk factors commonly assessed in the clinical practice would improve our ability to predict future cardiovascular events, critical issues remain to be specifically addressed. First, our current interpretation of the relationship between plasma CRP level and the risk for ischemic heart disease (IHD) in middle-aged men is based almost exclusively on data derived from cross-sectional or prospective nested casecontrol studies, 8 with only 1 populationbased study 9 conducted in a relatively small cohort of subjects. Second, the ability of plasma CRP levels to predict an increased risk for IHD has yet to be tested while considering a comprehensive number of lipid and nonlipid cardiovascular risk factors as confounders. Third, the CRP prognostic value of IHD risk showed a strong time-toevent dependency in the elderly, 10 whereas it appeared to be stable during follow-ups of varying lengths in a nested case-control studyinmiddle-agedmen. 3 Thus, the chronological relationship between plasma CRP levels and the risk for future IHD events remains to be fully elucidated using population-based, prospective data. The purpose of the present study was to examine the association between plasma 2474
2 SUBJECTS AND METHODS STUDY POPULATION AND FOLLOW-UP The Quebec Cardiovascular Study cohort has been described in detail previously. 11,12 In 1973, a random sample of 4637 men (aged years) was recruited using the provincial electoral lists from 7 cities of the Quebec metropolitan area for an evaluation of cardiovascular risk factors. Subsequent evaluations were performed at regular intervals, and data collected in 1985 were used as the baseline characteristics for the present prospective analyses. In 1985, 61.1% (n=2443) of the living cohort of men without IHD at the 1973 visit came to the lipid clinic in a fasting state for their evaluation. Among the 1557 other potential living participants, 10.0% could not be located, 18.8% showed up in a nonfasting state, and 71.4% refused to participate or underwent evaluation in a nonfasting state at their home by nurses of the project. Analyses of data collected in 1973 revealed that the age distribution of the 2443 participating men in 1985 was representative of the original cohort. During 1990 and 1991, all participants were contacted by mail and invited to answer a short standardized questionnaire on smoking habits, medication use, and history of cardiovascular diseases and diabetes mellitus. Telephone calls were made to participants who did not answer a second letter or, if unsuccessful, to a close family member. For those patients who reported cardiovascular diseases or diabetes and for those who died, hospital charts were reviewed. Mortality and morbidity data were obtained in 98.7% and 96.1%, respectively, of the participants of the 1973 initial screening. EVALUATION OF RISK FACTORS Data on demographic and lifestyle variables, medical history, and medication were obtained in 1985 through a standardized questionnaire administered to each participant by trained nurses and reviewed by a physician. Body weight and height were recorded. Resting blood pressure was measured after 5 minutes in a sitting position. The mean of 2 blood pressure measures obtained 5 minutes apart was used in the analyses. Information on personal and family history of IHD and diabetes, smoking habits, alcohol consumption, and medication use was also obtained. Diabetes was considered in men who self-reported the disease or who were treated with hypoglycemic agents. Only 1.1% of men were using hypolipidemic drugs in 1985, whereas 6.1% and 3.1% of men were using -blockers and diuretics, respectively, on a regular basis at the 1985 screening. Family history of IHD was considered positive if at least 1 parent and/or 1 sibling had a history of IHD. DEFINITION OF IHD EVENTS The diagnosis of a first IHD event included typical angina of effort, coronary insufficiency, nonfatal myocardial infarction, and coronary death. All myocardial infarctions met the criteria previously described, 11 ie, diagnostic electrocardiographic (ECG) changes alone or 2 of the following criteria: typical chest pain lasting at least 20 minutes, creatine kinase enzyme level at least twice the upper limit of the reference range, or characteristic ECG changes. Coronary insufficiency was considered if a typical retrosternal chest pain lasting at least 15 minutes was associated with transient ischemic ECG changes but without substantial elevation in levels of creatine kinase. Diagnoses of myocardial infarction and coronary insufficiency were all confirmed using hospital medical charts. All ECGs were read by the same cardiologist (G.R.D.), who was unaware of the participants risk profile. The diagnosis of angina of effort, obtained by a cardiologist of the study (G.R.D.), was based on typical symptoms of retrosternal squeezing or pressuretype discomfort occurring on exertion and relieved by rest and/or nitroglycerine. Criteria for the diagnosis of coronary deaths included confirmation from death certificate or autopsy report describing the presence of coronary disease, without evidence of noncardiac disease that could explain death. Myocardial infarction was considered fatal if death occurred within 4 weeks of the initial event or if it Continued on next page CRP levels and the risk for future IHD when controlling for a significant set of IHD risk factors in the prospective, population-based Quebec Cardiovascular Study. Baseline plasma CRP concentrations were measured in the entire cohort of 2037 middle-aged men initially free of clinical manifestations of IHD, among whom 105 developed IHD during the 5-year follow-up. RESULTS The baseline characteristics of the 2037 men who participated in the study are presented in Table 1. Men with incident IHD were older at baseline (P.001) and had a higher systolic blood pressure (P.001) and a higher prevalence of type 2 diabetes (P.001), compared with men who remained free of clinical manifestations of IHD during the 5-year follow-up. Plasma concentrations of total cholesterol (P.001), LDL cholesterol (P.001), triglycerides (P.001), and CRP (P=.01) were all significantly higher among those with incident IHD compared with IHD-free individuals. The 105 subjects who subsequently had a first IHD event during the 5-year follow-up also had reduced HDL cholesterol concentrations compared with those who did not (P.001). The magnitude of the association between lipid or nonlipid risk factors and plasma CRP levels was estimated by correlation analyses in the entire cohort. Similar results were obtained among subjects with incident IHD and IHD-free subjects, taken separately (results not shown). Plasma CRP concentrations were weakly but significantly correlated with levels of triglycerides (r=0.21; P.001), total cholesterol (r=0.06; P=.004), LDL cholesterol (r=0.06; P=.009), BMI (r=0.22; P.001), and HDL cholesterol (r= 0.23; P.001). Age and systolic blood pressure were also significant correlates of plasma CRP concentrations (r=0.17 and r=0.18, respectively; P.001). Higher plasma CRP levels were documented among smokers and diabetic subjects (P.001 for both). Figure 1 depicts the Kaplan-Meier event-free survival curves according to plasma CRP levels equal to or 2475
3 was diagnosed at autopsy. We confirmed IHD-related deaths from the Provincial Death Registry. Informed consent was obtained to review relevant hospital files. Autopsies were performed in about a third of deaths. The total IHD event frequency during the 5-year follow-up was similar in participants (5.4%) and nonparticipants (6.5%) in the study. LABORATORY ANALYSES Fasting lipoprotein-lipid and apolipoprotein levels were measured in fresh plasma samples in 1985 when participants came to the clinic for evaluation. Aliquots of fasting plasma frozen at time of collection were subsequently used for the assessment of baseline plasma CRP concentrations. Aliquots had been stored at 80 C since the 1985 baseline evaluation. Plasma cholesterol and triglyceride levels were determined on an autoanalyzer (Technicon RA-500; Bayer Corporation Inc, Tarrytown, NY) as previously described. 13 Plasma high-density lipoprotein (HDL) cholesterol levels were measured in the supernatant fraction after precipitation of apolipoprotein B containing lipoproteins using a combination of heparin and manganese chloride. 14 Low-density lipoprotein (LDL) cholesterol levels were estimated by means of the equation of Friedewald et al, 15 as men with triglyceride levels of greater than 400 mg/dl ( 4.5 mmol/l) (n=52) were excluded from the analyses. 12 Plasma apolipoprotein B levels were measured by means of the rocket immunoelectrophoresis method of Laurell, 16 as described previously. 13 The interassay coefficients of variation for cholesterol, HDL cholesterol, triglyceride, and apolipoprotein B levels were all less than 3%. Plasma CRP levels were measured using a commercially available, highly sensitive CRP assay (Behring Latex-Enhanced on the Behring Nephelometer BN-100; Behring Diagnostic, Westwood, Mass) and the calibrators provided by the manufacturer (N Rheumatology Standards SL; Behring Diagnostic). The sensitivity of the assay ranged from to 11 mg/l. The mean interassay coefficient of variation for plasma CRP levels calculated using 2 separate measures of the same aliquot in 134 men was less than 1% at low and high plasma CRP concentrations (data not shown). STATISTICAL ANALYSES Baseline characteristics of men in whom IHD developed during the 5-year follow-up were compared with the characteristics of those who remained free of clinical manifestations of IHD by the t test or the 2 statistic. Variables with a skewed distribution were logarithm-transformed, resulting in near-normal distributions. Geometric means were calculated and reported where indicated. Correlation analyses were performed using the Pearson and Spearman coefficients of correlation for parametric and nonparametric variables, respectively. We investigated the relationship between plasma CRP levels and the risk for future IHD events by dichotomizing plasma CRP levels using the median (1.77 mg/l) of the entire cohort and quartiles of plasma CRP levels. Both approaches yielded similar results. Thus, only data derived from the dichotomized CRP levels are presented. The Kaplan-Meier event-free survival probability (estimated probability of not having IHD during 5-year follow-up) was compared among men with elevated or low plasma CRP levels ( 1.77 or 1.77 mg/l, respectively). The log-rank test was used to compare the survival distributions. Cox proportional hazard models were used to estimate the risk for IHD associated with low or high plasma CRP concentrations. Relative risks were adjusted for potential confounding effects of age, smoking habits (smokers vs nonsmokers), diabetes mellitus (presence or absence), medication use at baseline (yes or no), systolic blood pressure, body mass index (BMI), and different plasma lipid variables. The potential confounding effects of age at baseline, smoking, and duration of follow-up in modulating the relationship between plasma CRP levels and the risk for future IHD events were investigated by introducing appropriate interaction terms into the multivariate Cox proportional hazard models. Statistical analyses were all performed using SAS software (SAS Institute, Cary, NC). above vs below the 50th percentile (1.77 mg/l) of the entire cohort. The log-rank test of the differences between both curves was significant (P=.004), indicating that men with plasma CRP levels of at least 1.77 mg/l were at greater risk for future IHD events compared with men having plasma CRP level of less than 1.77 mg/l. More specifically, among the 1016 subjects with plasma CRP levels of less than 1.77 mg/l, 39 had a first IHD event, whereas IHD developed in 66 men among the 1021 individuals with plasma CRP concentrations of at least 1.77 mg/l. The association between plasma CRP concentrations and the risk for future IHD events was investigated before and after adjustment for different lipid and nonlipid cardiovascular risk factors (Table 2). High plasma CRP concentrations ( 1.77 mg/l) were associated with a 1.8-fold increase in the relative risk (RR) for IHD (95% confidence interval [CI], ). Individual and simultaneous adjustment for the potential confounding effects of LDL cholesterol, the ratio of total cholesterol to HDL cholesterol, and triglyceride levels attenuated to some extent, but not completely, the increased risk for IHD associated with elevated plasma CRP levels. Similarly, the association between LDL cholesterol, the ratio of total cholesterol to HDL cholesterol, and triglyceride levels and the risk for IHD was not materially weakened after adjustment for plasma CRP levels (results not shown), suggesting independent influences of these variables on the risk for future IHD. The association between elevated plasma CRP levels and the risk for IHD remained significant when we controlled for the individual contributions of age, smoking status, diabetes, systolic blood pressure, medication use at baseline, or BMI (results not shown). On the other hand, plasma CRP levels of at least 1.77 mg/l did not predict an increased risk for IHD when the contribution of all nonlipid risk factors was simultaneously taken into consideration (model 6; RR, 1.2; 95% CI, ). We repeated the same analyses after stratifying the study population according to quartiles of plasma CRP concentrations. The crude RR for IHD associated with the highest quartile of plasma CRP levels ( 3.80 mg/l), using the lowest quartile as reference 2476
4 Table 1. Baseline Characteristics of the 2037 Study Participants* Variable Mean ± SD Range Age, y 56.5 ± Body mass index, kg/m ± Systolic blood pressure, mm Hg 130 ± Type 2 diabetes, No. (%) 102 (5.0)... Smokers, No. (%) 473 (23.2)... Total cholesterol, mg/dl 220 ± LDL cholesterol, mg/dl 151 ± HDL cholesterol, mg/dl 40 ± Triglycerides, mg/dl 155 ± Apolipoprotein B, mg/dl 117 ± CRP, median (interquartile range), mg/l 1.77 ( ) *LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; and CRP, C-reactive protein. Unless otherwise indicated. To convert to millimoles per liter, multiply by To convert to millimoles per liter, multiply by ( 0.85 mg/l), was 2.1 (95% CI, ). Adjustment for nonlipid traditional cardiovascular risk factors completely abolished the relationship between high plasma CRP levels (fourth quartile) and the risk for IHD (RR, 1.0; 95% CI, ). Excluding smokers from the analyses yielded results that were comparable to those obtained in the entire population. Further analyses were conducted to examine the relationship between plasma CRP levels and the risk for future IHD using hard end points only, ie, acute myocardial infarction and coronary death (n=61). Results were virtually identical to those obtained using the more generic IHD end point, which included cases of angina pectoris, coronary insufficiency, nonfatal myocardial infarction, and coronary death (results not shown). Indeed, elevated plasma CRP levels predicted an increased risk for IHD after adjustment for lipid risk factors but not after controlling simultaneously for several nonlipid risk factors. To evaluate whether the duration of follow-up affected the ability of plasma CRP levels to predict future IHD events independent of lipid and nonlipid risk factors, participants were stratified according to number of years of follow-up. Figure 2A shows that plasma CRP levels of at least 1.77 mg/l predicted an increased risk for future IHD events within the first 2 years of followup, but not beyond 2 years of follow-up. The baseline plasma CRP concentrations in individuals stratified according to the number of years of follow-up essentially matched its ability to predict the risk for IHD during the same period (Figure 2B). Indeed, plasma CRP levels at baseline were higher among men whose follow-up was less than 2 years compared with men for whom follow-up exceeded 2 years. Evidently, most men followed up for less than 4 years belonged to the group of individuals who had a first IHD event during the follow-up. When we considered only incident IHD cases (n=105), baseline plasma CRP levels were significantly higher among men who had their first event within 2 years of the baseline evaluation compared with those in whom Survival Probability <1.77 mg/l 1.77 mg/l Follow-up, y Figure 1. Kaplan-Meier survival curves according to plasma concentrations of C-reactive protein equal to or above vs below the 50th percentile (1.77 mg/l). Estimates of the survival probability were significantly different between groups (log-rank test, P=.004). Table 2. Multivariate Analysis of the 5-Year Relative Risk for IHD in Men With High Plasma CRP Levels* Adjustments RR for IHD (95% CI) P Value None 1.8 ( ).004 LDL cholesterol 1.7 ( ).008 Total/HDL cholesterol 1.5 ( ).06 Triglycerides 1.6 ( ).02 All lipid risk factors 1.5 ( ).05 Nonlipid risk factors 1.2 ( ).29 Fully adjusted 1.1 ( ).78 *Indicates before and after adjustment for plasma lipid-lipoprotein levels and nonlipid risk factors, including age, smoking status, history of diabetes, systolic blood pressure, medication use at baseline, and body mass index. IHD indicates ischemic heart disease; CRP, C-reactive protein; RR, relative risk; CI, confidence interval; LDL, low-density lipoprotein; and HDL, high-density lipoprotein. Indicates for men with CRP levels 1.77 mg/l, compared with men with levels 1.77 mg/l. Indicates all lipid and nonlipid risk factors. the event occurred more than 2 years into follow-up (geometric mean, 3.0 mg/l vs 1.9 mg/l; P=.03). Multivariate Cox proportional hazard analysis indicated that there was a significant interaction between duration of follow-up and plasma CRP levels in determining the risk for future IHD events, with plasma CRP levels of at least 1.77 mg/l predicting an increased risk for future IHD events only for a short follow-up (Table 3). Analyses were conducted to further examine the potential confounding effects of age at baseline on the relationship between plasma CRP levels and the risk for IHD. Plasma CRP concentrations among younger subjects were lower than in older middle-aged men (geometric means, 1.5 and 2.1 mg/l, respectively; P.001). Cox proportional hazard analysis showed that the multivariate term describing multiplicative interaction between age and plasma CRP levels was significant (P=.04). Thus, high plasma CRP levels predicted an increased risk for IHD, independent of the confounding effects of lipid and nonlipid cardiovascular risk factors, in younger but not in older individuals (Table 3). 2477
5 COMMENT A B Relative Risk for IHD CRP, mg/l P =.04 <1 4.3 P = >4 Follow-up, y Figure 2. A, Relative risks for future ischemic heart disease (IHD) events associated with high baseline plasma concentrations of C-reactive protein (CRP) ( 1.77 mg/l) according to the number of years of follow-up. B, Plasma CRP concentrations (geometric means) in subgroups of subjects stratified according to length of follow-up. Bars represent SEM. Asterisk indicates significantly different from follow-up of less than 1 year (P.001); dagger, significantly different from follow-up of 1 to 2 years (P.001). A number of clinically relevant observations can be drawn from this prospective, population-based study. First, plasma CRP levels of at least 1.77 mg/l were associated with an approximately 2-fold increase in the risk for future IHD events. Second, this increased risk for IHD associated with elevated plasma CRP levels remained significant in multivariate analyses only when considering events that occurred no later than 2 years into followup, but not when considering those that occurred beyond 2 years of follow-up. Third, elevated plasma CRP levels at baseline predicted an increased risk for a first IHD event independent of lipid and nonlipid cardiovascular risk factors in men younger than 55 years, but not in older individuals. CRP LEVEL VS TRADITIONAL CARDIOVASCULAR RISK FACTORS Plasma CRP is a nonspecific marker of underlying systemic inflammation. Levels of CRP fluctuate into a wide range of concentrations, depending on several stimuli. 17 Infections, physical trauma, and other inflammatory conditions clearly represent important sources of this variability. However, several other features, eg, age, 18 diabetes, 19 smoking status, 20 obesity, 21 exercise, 22 antiinflammatory drugs, 3 and lipid-lowering agents, 23 influence plasma CRP concentrations and IHD risk. Thus, any combination of these traditional risk factors could potentially confound the relationship between plasma CRP levels and IHD risk. To our knowledge, the Monitoring Trends and Determinations in Cardiovascular Disease (MONICA) study 9 is, to date, the only prospective, population-based study documenting the relationship between plasma CRP levels and the risk for future coronary events in a cohort of middle-aged men. It showed that the risk ratio of IHD events associated with a 1-SD increase in logarithm- CRP was 1.67 (95% CI, ) and 1.50 (95% CI, ), respectively, before and after adjustment for the combined confounding effect of age and smoking status. Similarly, we observed that individual adjustment for age and smoking habits did not materially affect the risk for IHD associated with high baseline plasma CRP concentrations (not shown). Further analyses indicated that the increased risk for IHD associated with elevated plasma Table 3. Effects of Duration of Follow-up and Age at Baseline on Unadjusted and Adjusted Relative Risks for IHD* Subgroup Analysis Unadjusted Adjusted for Lipid Risk Factors RR (95% CI) Adjusted for Nonlipid Risk Factors Fully Adjusted Effect of duration of follow-up Short-term ( 2 y) 3.3 ( ) 2.8 ( ) 2.3 ( )# 2.0 ( )** Long-term ( 2 y) 1.2 ( ) 1.0 ( ) 0.9 ( ) 0.7 ( ) Effect of age at baseline 55 y 3.9 ( ) 3.3 ( ) 2.9 ( ) 2.6 ( )# 55 y 1.0 ( ) 0.8 ( ) 0.8 ( ) 0.7 ( ) *Indicates for men with CRP levels of at least 1.77 mg/l. Explanation of abbreviations is given in the first footnotes to Tables 1 and 2. Includes triglycerides and LDL cholesterol levels, and the ratio of total cholesterol to HDL cholesterol. Includes age, smoking status, history of diabetes, systolic blood pressure, medication use at baseline, and body mass index. Indicates all lipid and nonlipid risk factors. P.001. P.007. #P.02. **P =
6 CRP concentrations remained significant even after adjustment for these 2 risk factors simultaneously (RR, 1.5; 95% CI, ; P=.04). On the other hand, the relationship between plasma CRP concentrations and the risk for future IHD events was substantially attenuated when other nonlipid risk factors (diabetes, hypertension, and BMI) were considered simultaneously (RR, 1.2; 95% CI, ). Thus, results from the present study suggest that the relationship between plasma CRP levels and the risk for future IHD events is not independent of the sum of nonlipid risk factors. These findings are in contrast with those of a previous prospective nested case-control study in middleaged men, which suggested that the risk for IHD associated with elevated plasma CRP levels was not modified by other risk factors, 3 including those that were controlled for in the present study. In this regard, it should be pointed out that the study by Koenig et al, Ridker as well as other studies, 9,10 did not report the impact that a simultaneous adjustment for a comprehensive list of lipid and nonlipid cardiovascular risk factors may have had on the relationship between plasma CRP concentrations and the risk for future IHD events. Results from our large, prospective, population-based study underline the impact that a number of relatively weak correlates of CRP (r 2 5%) such as age, systolic blood pressure, and smoking habits may exert on the relationship between plasma CRP levels and the risk for future IHD events. Indeed, although not confounding singularly, these risk factors greatly attenuated the association between CRP and the risk for future IHD events when they were considered simultaneously. CRP LEVEL VS DURATION OF FOLLOW-UP Results from the present population-based study also indicated that the relationship between plasma CRP levels and the risk for future IHD onset was strong during a short-term follow-up, but virtually absent during a longer follow-up. Specifically, increased plasma CRP levels were associated with a 2-fold increase in the risk for IHD during the first 2 years of follow-up, even after adjustment for a series of lipid and nonlipid cardiovascular risk factors. On the other hand, the relationship between high baseline plasma CRP concentrations and incident IHD was no longer apparent beyond 2 years of follow-up. It has been suggested that increased plasma CRP levels may reflect the presence of unstable plaques, 24 which may be associated with a subsequent IHD event during a shorter time than stable plaques or atherosclerosis. This hypothesis is consistent with the fact that individuals who had IHD within the first 2 years of follow-up were characterized by higher baseline plasma CRP levels than patients in whom IHD occurred more than 2 years into the follow-up. These results provide further insight into our understanding of the chronological relationship between CRP and the risk for future coronary events, which essentially remained unresolved to date. Indeed, Ridker et al 3 found that the risk for arterial thrombosis associated with increasing plasma CRP levels was stable during long periods of follow-up. On the other hand, results from the Helsinki Ageing Study in elderly subjects suggested that increased plasma CRP levels predicted cardiovascular events less than 1 year after blood collection better than events that occurred after 1 year of follow-up. 10 The nested case-control design of the study by Ridker et al 3 and the limited number of subjects in the Helsinki Ageing Study (N=455) 10 limited our ability to draw firm conclusions as to the confounding effect of follow-up duration on the relationship between plasma CRP levels and the risk for IHD. The population-based design of our study, the size of the study cohort, and the analytical strategy used (timecensoring design vs case-control approach, which does not take into account the time of the event in the matching procedure) provided a more valid model for the analysis of the IHD risk associated with elevated plasma CRP levels in relation to the duration of follow-up compared with previous nested case-control and smaller prospective studies. As in previous studies, however, we measured plasma CRP levels only once. Whether having a more stable CRP concentration by measuring it more than once would have modified this time-dependent relationship between elevated plasma CRP levels and IHD onset remains to be clarified. CRP LEVEL VS AGE AT BASELINE Among the correlates of plasma CRP concentrations, age was of particular interest. Indeed, results from our study indicated that elevated plasma CRP levels predicted an increased IHD risk independent of all other confounding risk factors in younger but not in older individuals. This observation was rather unexpected, because older individuals tended to have higher plasma CRP levels at baseline than did younger subjects in the present study and in other reports. 18,25 It could be speculated that a greater number of possible covariates of plasma CRP levels, including cardiovascular risk factors and possibly other conditions associated with an increasing inflammatory response with aging, 26 could dilute to a greater extent the impact of high plasma CRP levels on IHD risk in older compared with younger subjects. Thus, although younger men had lower plasma CRP concentrations than did older men, the increased risk for IHD associated with increasing plasma CRP levels was independent of the simultaneous confounding effects of lipid and nonlipid cardiovascular risk factors only in the younger men. These results in middle-aged men concur with recent observations by Strandberg and Tilvis, 10 who have suggested that the ability of plasma CRP levels to predict the risk for IHD in the elderly was diluted in older individuals. CONCLUSIONS To the best of our knowledge, the Quebec Cardiovascular Study is the first large-scale, population-based prospective study of the relationship between plasma CRP levels, a marker of systemic inflammation, and the risk for future IHD events in men. Our results have indicated that (1) high plasma CRP levels were associated with an increased risk for future IHD events, independent of concomitant variations in plasma lipid levels and of a series of nonlipid risk factors in short-term ( 2 years) 2479
7 but not long-term ( 2 years) follow-up; and (2) elevated plasma CRP levels were an independent predictor of future IHD events in younger but not in older men. These results suggest that measuring plasma CRP levels in an integrated strategy for primary prevention of IHD could be useful, but only in specific situations. Particularly, younger middle-aged men may benefit the most from having their plasma CRP levels measured for short- to long-term assessment of IHD risk. Future studies will be needed to validate and confirm these hypotheses. Accepted for publication September 29, This study was supported in part by operating grant MOP from the Canadian Institutes for Health Research (Ottawa, Ontario), and by an unrestricted Medical School Grant from Merck-Frosst (Kirkland, Quebec). Dr Bergeron is a clinical scientist supported by the Fonds de la Recherche en Santé du Québec (Montréal). Dr Lamarche is the recipient of a Canada Research Chair in Nutrition, Functional Foods, and Cardiovascular Risk. Corresponding author and reprints: Benoît Lamarche, PhD, Lipid Research Center, R-9600, CHUL Research Center, 2705 Laurier Blvd, Ste-Foy, Québec, Canada G1V 4G2 ( benoit.lamarche@crchul.ulaval.ca). REFERENCES 1. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97: Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med. 1998;46: Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336: Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342: Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349: Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98: Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97: Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100: Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to Circulation. 1999;99: Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol. 2000; 20: Dagenais GR, Robitaille NM, Lupien PJ, et al. First coronary heart disease event rates in relation to major risk factors: Québec Cardiovascular Study. Can J Cardiol. 1990;6: Lamarche B, Després JP, Moorjani S, et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol. 1995;75: Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36: Albers JJ, Warnick GR, Wiebe D, et al. Multi-laboratory comparison of three heparin-mncl2 precipitation procedures for estimating cholesterol in highdensity lipoproteins. Clin Chem. 1978;24: Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18: Laurell CB. Electroimmunoassay. Scand J Clin Lab Med. 1972;124: Pepys MB. C-reactive protein fifty years on. Lancet. 1981;1: Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999;84: Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40: Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144: Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282: Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med. 2000;21: Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100: Stefanadis C, Diamantopoulos L, Dernellis J, et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol. 2000;32: Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312: Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:
Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study
Atherosclerosis 182 (2005) 315 321 Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study Annie C. St-Pierre a,b, Bernard Cantin
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationThe New England Journal of Medicine C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN PAUL M. RIDKER, M.D., CHARLES H. HENNEKENS, M.D., JULIE E. BURING, SC.D., AND NADER RIFAI, PH.D.
More informationClinical Investigation and Reports. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Clinical Investigation and Reports Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein Paul M. Ridker, MD; Nader Rifai, PhD; Marc A. Pfeffer, MD; Frank Sacks, MD; Eugene Braunwald,
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More informationModerate alcohol consumption is associated with decreased
Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with
More informationC-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationDyslipidemia, hypertension, smoking, and diabetes are
Inflammation-Sensitive Plasma Proteins and Incidence of Myocardial Infarction in Men With Low Cardiovascular Risk Gunnar Engström, Lars Stavenow, Bo Hedblad, Peter Lind, Patrik Tydén, Lars Janzon, Folke
More informationC-Reactive Protein Levels and Outcomes after Statin Therapy
The new england journal of medicine original article C-Reactive Protein Levels and Outcomes after Statin Therapy Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D.,
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More informationEmma Barinas-Mitchell, 1 Mary Cushman, 2 Elaine N. Meilahn, 1 Russell P. Tracy, 3 and Lewis H. Kuller 1
American Journal of Epidemiology Copyright 2001 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 153, No. 11 Printed in U.S.A. C-reactive Protein in Postmenopausal
More informationAssociation of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions
ORIGINAL ARTICLE J Nepal Med Assoc 2011;51(184):157-63 Association of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions Shrestha R 1, Jha
More informationPrevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values
Papers in Press. First published June 17, 2004 as doi:10.1373/clinchem.2004.036004 Clinical Chemistry 50:9 000 000 (2004) Lipids, Lipoproteins, and Cardiovascular Risk Factors Prevalence of High C-Reactive
More informationPatients with the metabolic syndrome are at increased risk
Clinical Investigation and Reports C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women Paul M Ridker, MD;
More informationPlasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack. The Framingham Study
Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack The Framingham Study Natalia S. Rost, MA; Philip A. Wolf, MD; Carlos S. Kase, MD; Margaret Kelly-Hayes,
More informationEpidemiology. C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes The Strong Heart Study
Epidemiology C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes The Strong Heart Study Lyle G. Best, MD; Ying Zhang, PhD; Elisa T. Lee, PhD; Jeun-Liang
More informationDespite the availability of effective preventive therapies,
Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals Robert Park, MD; Robert Detrano, MD, PhD; Min Xiang,
More informationFasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease
Original Contributions Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease Benoît Lamarche, PhD; André Tchernof, PhD; Pascale
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationGender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity
71 P.P.Bidzilya Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine
More informationIn an attempt to improve global cardiovascular risk
MINI-REVIEW: EXPERT OPINIONS Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention Paul M Ridker, MD In an attempt to improve global cardiovascular risk prediction,
More informationOf the 1.5 million heart attacks
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke Paul M Ridker, MD, MPH Of the 1.5 million heart attacks and 600 000 strokes
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 A PRIL 3, 1997 NUMBER 14 INFLAMMATION, ASPIRIN, AND THE RISK OF CARDIOVASCULAR DISEASE IN APPARENTLY
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAssessing Cardiovascular Disease Risk with HS-C-reactive. California Technology Assessment Forum
TITLE: Assessing Cardiovascular Disease Risk with HS-C-reactive Protein AUTHOR: Judith Walsh, M.D., MPH Professor of Medicine Division of General Internal Medicine Department of Medicine University of
More informationJAMA. 2005;294:
ORIGINAL CONTRIBUTION Non HDL Cholesterol, Apolipoproteins A-I and B 100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women Paul M Ridker, MD Nader Rifai,
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationEvaluation of hs-crp levels in acute coronary syndromes
Original Research Article Evaluation of hs-crp levels in acute coronary syndromes R. S. Pushpa Kumari 1*, Priya John 2, V. A. Vipula 3 1 Professor, Department of General Medicine, MNR Medical College and
More informationThe development of atherosclerosis is now considered to
C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis Hiroyuki Hashimoto, MD; Kazuo Kitagawa, MD, PhD; Hidetaka Hougaku, MD, PhD; Yoshiomi Shimizu, MD;
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationORIGINAL INVESTIGATION
Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men The Quebec Cardiovascular Study ORIGINAL INVESTIGATION Isabelle Lemieux,
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population
Journal of the American College of Cardiology Vol. 51, No. 9, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.048
More informationInflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationPAPER Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians
(2001) 25, 1327 1331 ß 2001 Nature Publishing Group All rights reserved 0307 0565/01 $15.00 www.nature.com/ijo PAPER Relation of C-reactive protein to body fat distribution and features of the metabolic
More informationC-Reactive Protein and Angiographic Coronary Artery Disease: Independent and Additive Predictors of Risk in Subjects With Angina
Journal of the American College of Cardiology Vol. 39, No. 4, 2002 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(01)01804-6 C-Reactive
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationORIGINAL ARTICLES. Associations between body mass index and serum levels of C-reactive protein. Materials and methods.
Associations between body mass index and serum levels of C-reactive protein Tung-Wei Kao, I-Shu Lu, Kuo-Chen Liao, Hsiu-Yun Lai, Ching-Hui Loh, Hsu-Ko Kuo Background. Obesity leads to increased risk of
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationBody Mass Index and C-Reactive Protein in the Healthy Korean Aged Men
J Korean Med Sci 2006; 21: 811-5 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Body Mass Index and C-Reactive Protein in the Healthy Korean Aged Men The purpose of this study was to determine
More informationInfluence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial
JACC Vol. 33, No. 1 January 1999:125 30 125 Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial MARC A. PFEFFER, MD, PHD, FACC, FRANK M. SACKS, MD, LEMUEL A. MOYÉ, MD, PHD,*
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationResearch Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers
International Inflammation Volume 2012, Article ID 124693, 5 pages doi:10.1155/2012/124693 Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers Yaron Arbel,
More informationLow ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients
Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients N. Peltz-Sinvani, MD 1,4,R.Klempfner,MD 2,4, E. Ramaty, MD 1,4,B.A.Sela,PhD 3,4,I.Goldenberg,MD
More informationHigh Sensitive C-Reactive Protein (hs-crp) and its Correlation with Angiographic Severity of Coronary Artery Disease (CAD)
ORIGINAL ARTICLE JIACM 2007; 8(3): 217-21 High Sensitive C-Reactive Protein (hs-crp) and its Correlation with Angiographic Severity of Coronary Artery Disease (CAD) Tenzin Nyandak*, Arun Gogna**, Sandeep
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationAssociation Between Consumption of Beer, Wine, and Liquor and Plasma Concentration of High-Sensitivity C-Reactive Protein in Women Aged 39 to 89 Years
Association Between Consumption of Beer, Wine, and Liquor and Plasma Concentration of High-Sensitivity C-Reactive Protein in Women Aged 39 to 89 Years Emily B. Levitan, MS a,e, Paul M. Ridker, MD, MPH
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationCoronary heart disease (CHD) is the leading cause of
Serum Albumin and Risk of Myocardial Infarction and All-Cause Mortality in the Framingham Offspring Study Luc Djoussé, MD, DSc; Kenneth J. Rothman, DrPH; L. Adrienne Cupples, PhD; Daniel Levy, MD; R. Curtis
More informationIntermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis
Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which
More informationCross-sectional data have shown positive associations between
Blood Pressure Increase and Incidence of Hypertension in Relation to Inflammation-Sensitive Plasma Proteins Gunnar Engström, Lars Janzon, Göran Berglund, Peter Lind, Lars Stavenow, Bo Hedblad, Folke Lindgärde
More informationORIGINAL INVESTIGATION. High Attributable Risk of Elevated C-Reactive Protein Level to Conventional Coronary Heart Disease Risk Factors
ORIGINAL INVESTIGATION High Attributable Risk of Elevated C-Reactive Protein Level to Conventional Coronary Heart Disease Risk Factors The Third National Health and Nutrition Examination Survey Michael
More informationJournal of the American College of Cardiology Vol. 37, No. 8, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 8, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01289-X Coronary
More informationWhat s New in Cardiac Testing?
What s New in Cardiac Testing? Payam Dehghani, MD, FRCPC; Dobri Hazarbasanov, MD; and Andrew Ignaszewski, MD, FRCPC Presented at UBC s Diabetes and Cardiology Update, 2003 Susan s concern Susan, 55, comes
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationEpidemiological evidence suggests that blood pressure (BP)
Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke Mario Di Napoli, MD; Francesca Papa, MD Background
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More informationMagnesium intake and serum C-reactive protein levels in children
Magnesium Research 2007; 20 (1): 32-6 ORIGINAL ARTICLE Magnesium intake and serum C-reactive protein levels in children Dana E. King, Arch G. Mainous III, Mark E. Geesey, Tina Ellis Department of Family
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationC-reactive protein (CRP), a marker of the reactant plasma
Thrombosis C-Reactive Protein, Fibrin D-Dimer, and Risk of Ischemic Heart Disease The Caerphilly and Speedwell Studies G.D.O. Lowe, P.M. Sweetnam, J.W.G. Yarnell, A. Rumley, C. Rumley, D. Bainton, Y. Ben-Shlomo
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationSupplementary Online Content
Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant
More informationSupplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationChest pain and subsequent consultation for coronary heart disease:
Chest pain and subsequent consultation for coronary heart disease: a prospective cohort study Peter R Croft and Elaine Thomas ABSTRACT Background Chest pain may not be reported to general practice but
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationBeyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
More informationARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients
ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationCombined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women
European Heart Journal (2002) 23, 528 535 doi:10.1053/euhj.2001.2888, available online at http://www.idealibrary.com on Combined effects of systolic blood pressure and serum cholesterol on cardiovascular
More information